Integrated Omics Analysis of Pain: Omics Data Generation Center

疼痛的综合组学分析：组学数据生成中心

• 批准号: 10611195
• 负责人: TIMOTHY D HOWARD
• 金额: $ 50万
• 依托单位: WAKE FOREST UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-01 至 2023-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10611195
• 关键词: Acute; Administrative Supplement; Biological Markers; California; Charge; Collaborations; Complement; Data; Ensure; Funding; Generations; Goals; Hybrids; Lipids; Liquid Chromatography; Mass Fragmentography; Operative Surgical Procedures; Pain; Participant; Patient Recruitments; Patients; Plasma; Resolution; Sampling; Surface; Universities; base; biomarker signature; chronic pain; clinical research site; forest; lipidomics; medical schools; metabolomics; novel; pain chronification; participant enrollment; precision medicine

SUMMARY The goal of the WF ODGC is to generate metabolomics and lipidomics data on plasma samples collected from participants of the A2CPS Consortium, and to discover novel metabolomic and/or lipidomic signatures that are associated with the conversion from acute to chronic pain. We use high resolution HILIC-MS/MS and high resolution GC-MS for the characterization of metabolites, and charged surface hybrid liquid chromatography- high resolution accurate mass MS/MS in positive and negative electrospray mode to characterize plasma lipids. The ODGC is a collaboration between the Center for Precision Medicine at the Wake Forest University School of Medicine and the West Coast Metabolomics Center at the University of California at Davis. This request for an Administrative Supplement is necessitated by the unforeseen delay in patient recruitment and enrollment at the two Clinical sites, MCC1 and MCC2, and the resulting delay in sample analysis at the ODGC. Based on the estimates from the MCCs, it is anticipated that all samples for metabolomics and lipidomics analysis (8400 samples total) will be collected by the end of August 2025, and analysis, data and sample transfer will be completed by the ODGC by the end of May, 2026. The requested supplement will ensure the successful analysis of the entire complement of samples, characterization and quantification of preselected secondary biomarkers, and integration of the resulting biomarker data with other biomarker information collected for the Consortium.

概括 WF ODGC的目的是生成有关从中收集的血浆样品的代谢组学和脂质组学数据 A2CPS联盟的参与者，并发现新型代谢组和/或脂质组学特征 与从急性到慢性疼痛的转化有关。我们使用高分辨率Hilic-MS/MS和高分 分辨率GC-MS用于代谢物的表征和带电的表面杂化液相色谱 - 高分辨率准确的质量MS/MS在正和负电喷雾模式下以表征血浆脂质。 ODGC是Wake Forest University School的精密医学中心之间的合作 加利福尼亚大学戴维斯分校的医学和西海岸代谢组学中心。 由于无法预料的患者招聘延迟，需要提出这种行政补充的要求 以及在两个临床部位MCC1和MCC2的注册，以及在样本分析中的延迟 ODGC。根据MCC的估计值，预计所有用于代谢组学和脂肪组学的样本 分析（总共8400个样本）将在2025年8月底之前收集，并分析，数据和样本转移 将由ODGC到2026年5月底完成。请求的补充剂将确保成功 分析样品的整个补充，预选次级的表征和定量 生物标志物以及所得生物标志物数据与收集的其他生物标志物信息的集成 财团。